JP2010513901A5 - - Google Patents

Download PDF

Info

Publication number
JP2010513901A5
JP2010513901A5 JP2009542216A JP2009542216A JP2010513901A5 JP 2010513901 A5 JP2010513901 A5 JP 2010513901A5 JP 2009542216 A JP2009542216 A JP 2009542216A JP 2009542216 A JP2009542216 A JP 2009542216A JP 2010513901 A5 JP2010513901 A5 JP 2010513901A5
Authority
JP
Japan
Prior art keywords
peptide
seq
fragment
hox
homeodomain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009542216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513901A (ja
JP5683108B2 (ja
Filing date
Publication date
Priority claimed from GBGB0625321.5A external-priority patent/GB0625321D0/en
Application filed filed Critical
Publication of JP2010513901A publication Critical patent/JP2010513901A/ja
Publication of JP2010513901A5 publication Critical patent/JP2010513901A5/ja
Application granted granted Critical
Publication of JP5683108B2 publication Critical patent/JP5683108B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009542216A 2006-12-19 2007-12-19 癌バイオマーカー Expired - Fee Related JP5683108B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0625321.5 2006-12-19
GBGB0625321.5A GB0625321D0 (en) 2006-12-19 2006-12-19 Cancer biomarker
GB0719792.4 2007-10-10
GBGB0719792.4A GB0719792D0 (en) 2006-12-19 2007-10-10 Cancer biomarkers
PCT/GB2007/004902 WO2008075056A1 (en) 2006-12-19 2007-12-19 Cancer biomarkers

Publications (3)

Publication Number Publication Date
JP2010513901A JP2010513901A (ja) 2010-04-30
JP2010513901A5 true JP2010513901A5 (OSRAM) 2011-01-27
JP5683108B2 JP5683108B2 (ja) 2015-03-11

Family

ID=39265269

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009542216A Expired - Fee Related JP5683108B2 (ja) 2006-12-19 2007-12-19 癌バイオマーカー

Country Status (19)

Country Link
US (1) US8460882B2 (OSRAM)
EP (1) EP2115472B1 (OSRAM)
JP (1) JP5683108B2 (OSRAM)
CN (1) CN101675341B (OSRAM)
AU (1) AU2007335999B2 (OSRAM)
BR (1) BRPI0720371B8 (OSRAM)
CA (1) CA2671939C (OSRAM)
CY (1) CY1115178T1 (OSRAM)
DK (1) DK2115472T3 (OSRAM)
ES (1) ES2445185T3 (OSRAM)
GB (2) GB0625321D0 (OSRAM)
IL (1) IL199241A (OSRAM)
MX (1) MX2009006378A (OSRAM)
NZ (1) NZ577548A (OSRAM)
PL (1) PL2115472T3 (OSRAM)
PT (1) PT2115472E (OSRAM)
RU (1) RU2460075C2 (OSRAM)
SI (1) SI2115472T1 (OSRAM)
WO (1) WO2008075056A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
DE102006047617B4 (de) 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
DE102008017216B4 (de) 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
GB0823445D0 (en) * 2008-12-23 2009-01-28 Univ Surrey Biomarker
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
GB0912175D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
AU2010272371A1 (en) * 2009-07-13 2012-02-02 The University Of Surrey Therapeutic peptides, polypeptides ans nucleic acid sequences
GB0912190D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
GB0921329D0 (en) * 2009-12-04 2010-01-20 Univ Surrey Biomarker
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
AU2012252426A1 (en) * 2011-05-12 2013-11-28 Noviogendix Research B.V. Molecular markers in prostate cancer
US20140106363A1 (en) * 2011-05-12 2014-04-17 Noviogendix Research B.V. Molecular markers in prostate cancer
WO2013037118A1 (zh) * 2011-09-16 2013-03-21 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
MX2014006662A (es) * 2011-12-05 2015-04-16 Phigenix Inc Direccionamiento de en2, pax2, y/o defb1 para tratamiento de afecciones de la próstata.
WO2014005138A1 (en) * 2012-06-29 2014-01-03 Kerschensteiner Daniel A Colorimetric gelatinase assay
US10613087B2 (en) * 2012-08-10 2020-04-07 Analiza, Inc. Methods and devices for analyzing species to determine diseases
WO2014179959A1 (en) * 2013-05-09 2014-11-13 The Procter & Gamble Company Method and system for assessing health condition
WO2016102560A1 (en) * 2014-12-23 2016-06-30 The University Of Surrey Glycosylated biomarker
KR101698654B1 (ko) 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
ES2861316T3 (es) * 2015-05-29 2021-10-06 Koninklijke Philips Nv Métodos para pronosticar cáncer de próstata
CN108289929A (zh) * 2015-09-23 2018-07-17 国家科学研究中心 用于治疗神经退行性障碍的同源异型蛋白
CN106282347A (zh) * 2016-08-17 2017-01-04 中南大学 HoxC11作为生物标志物在制备肺腺癌的预诊断试剂中的应用
JP6855579B2 (ja) * 2016-12-28 2021-04-07 中国科学院広州生物医薬与健康研究院Guangzhou Institutes Of Biomedicine And Health,Chinese Academy Of Sciences T細胞を得る方法及び使用
KR101777085B1 (ko) 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
KR101777259B1 (ko) * 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
KR101777254B1 (ko) 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
CN107894507A (zh) * 2017-11-22 2018-04-10 南宁科城汇信息科技有限公司 一种发现和鉴定肝癌血清差异表达蛋白和验证标志物蛋白方法
CN107727729A (zh) * 2017-11-22 2018-02-23 南宁科城汇信息科技有限公司 一种oa候选标志物诊断模型的建立方法
KR101923199B1 (ko) 2018-04-25 2018-11-28 주식회사 무진메디 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물
CN111363817B (zh) * 2018-12-26 2024-02-02 广州康立明生物科技股份有限公司 基于hoxd12基因的肺癌诊断剂及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000498A1 (en) * 1997-06-27 1999-01-07 Human Genome Sciences, Inc. Human nk-3 related prostate specific gene-1
RU2234942C2 (ru) * 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
JP2002527758A (ja) * 1998-10-19 2002-08-27 ダイアデクスアス・インコーポレーテッド 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法
AU2001263771A1 (en) 2000-05-30 2001-12-11 Danmarks Miljo Undersogelser An assay method and kit for testing biological material for exposure to stress using biomarkers
AU2001277521A1 (en) * 2000-06-30 2002-01-14 Epigenomics Ag Diagnosis of diseases associated with cell signalling
US20050079492A1 (en) * 2000-09-12 2005-04-14 Burgess Jr. Robert M. Micro-arrayed organization of transcription factor target genes
NZ527180A (en) 2000-12-24 2007-02-23 Iser Lubocki A method for detecting biomarkers
US20040063216A1 (en) 2000-12-24 2004-04-01 Iser Lubocki Method for detecting biomarkers
JP2004529630A (ja) * 2001-03-01 2004-09-30 エピゲノミクス アーゲー 診断および治療目的の遺伝子パネルを遺伝子の発現およびメチル化状態に基づいて開発する方法
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
CA2469089A1 (en) * 2003-07-08 2005-01-08 Institut De Recherches Cliniques De Montreal En-2 gene, disgnostic and therapeutic uses thereof
US20060014301A1 (en) 2004-07-13 2006-01-19 Power3 Medical Products, Inc. Antibody-based system for detection of differential protein expression patterns
EP2280084B1 (en) * 2004-12-02 2015-02-11 Epigenomics AG Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
US9416422B2 (en) * 2005-02-18 2016-08-16 Sloan-Kettering Institute For Cancer Research Methods for detecting minimum residual disease

Similar Documents

Publication Publication Date Title
JP2010513901A5 (OSRAM)
RU2009127774A (ru) Биомаркеры рака
Hudler et al. Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics
US10345309B2 (en) Biomarkers for gastric cancer and uses thereof
EP2796878A1 (en) New biomarkers for diagnosis, prediction and/or prognosis of sepsis and uses thereof
US20220268776A1 (en) Biomarker panel for diagnosing pancreatic cancer and use thereof
JP4916441B2 (ja) 結腸直腸腺腫及び/又は癌腫に対するバイオマーカーとしてのトランスサイレチンの使用;検出方法及び試験システム
JP6774925B2 (ja) 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療のための方法並びにそのキット
WO2021076036A1 (en) Apparatuses and methods for detection of pancreatic cancer
KR101520615B1 (ko) 간암 진단용 바이오 마커
JP4516124B2 (ja) 肝線維症の診断方法
EP2569451A1 (en) Methods and devices for diagnosing alzheimers disease
US20130210667A1 (en) Biomarkers for Predicting Kidney and Glomerular Pathologies
CN104272112B (zh) 用于帮助诊断中风的基于生物标记的方法和生物芯片
JP2016530545A (ja) 卵巣がんに関するバイオマーカー
AU2014247083B2 (en) Methods and arrays for use in biomarker detection for prostate cancer
JP2012526543A5 (OSRAM)
KR20180106889A (ko) 삼중음성 유방암의 항암제에 대한 반응 및 예후 측정용 바이오마커
US20140248637A1 (en) Composition for diagnosis of lung cancer and diagnosis kit of lung cancer
KR20230113742A (ko) 난소암의 검출 및 치료를 위한 방법
WO2020021026A1 (en) Method of diagnosing asthma subtypes
WO2023230584A1 (en) Methods and systems for risk stratification and management of bladder cancer
KR102235718B1 (ko) 방광암 진단 또는 예후 분석용 바이오마커 조성물, 키트 및 이를 이용한 진단 방법
KR102136747B1 (ko) 장형 위암의 예후 진단 마커
CN120442791B (zh) 非功能性胰腺神经内分泌肿瘤预后标志物及其应用